Teoxane (RHA Collection): Resilient Hyaluronic Acid, FDA PMA P170002, and the MAUDE Record

What is Teoxane's RHA Collection, how is it structured under FDA PMA P170002, what makes resilient hyaluronic acid different, and what does the MAUDE record show?

Teoxane SA (Geneva, Switzerland; global brand TEOSYAL) markets its US portfolio under a single FDA PMA, P170002, approved 2017-10-19 for RHA 2, RHA 3, and RHA 4 — the first FDA-approved hyaluronic-acid fillers designed for dynamic facial wrinkles and folds (moderate-to-severe nasolabial folds in adults 22+). P170002 has since accumulated 52 supplements (through 2026-05-12) adding RHA Redensity (perioral/lipstick lines), RHA Dynamic Volume (midface), and the RHA Mepi (mepivacaine) line described as the first major anesthetic innovation in HA fillers in nearly 20 years. The technology is Resilient Hyaluronic Acid made via Preserved Network Technology (PNT), a gentle, heatless manufacturing process that preserves more of the natural HA network (less chemical cross-linking) so the gel moves with facial expressions; RHA lasts up to 15 months in dynamic wrinkles and folds and up to a year in cheeks, lips, and lipstick lines. openFDA MAUDE lists 712 reports under RHA/TEOSYAL brand names (700 Injury, 11 Malfunction, 1 Death under the global TEOSYAL RHA3 name); Teoxane has zero FDA recalls. Teoxane has 17 ClinicalTrials.gov-sponsored studies.

---

How is Teoxane's US portfolio structured under the single FDA PMA P170002, and what is the RHA approval timeline?

A unique aspect of Teoxane's regulatory footprint in the United States is that its entire dermal filler portfolio is consolidated under a single Premarket Approval (PMA) family: P170002. This single-PMA structure contrasts with competitors like Allergan Aesthetics (which registers Juvéderm products across multiple separate PMAs) or Galderma (which holds four distinct PMA families).

The original applicant for P170002 is Teoxane SA, based in Geneva, Switzerland. The U.S. commercialization of the portfolio has historically been driven by Revance Aesthetics (a division of Revance Therapeutics, Inc.) under an exclusive distribution agreement, which positioned the RHA Collection as a premium "designer filler" portfolio. This distribution relationship was subsequently impacted by Crown Laboratories' acquisition of Revance in late 2024, but the underlying regulatory ownership remains with Teoxane.

RHA Regulatory Timeline

The accumulation of 52 supplements under P170002 reflects a phased expansion of products and indications (all RHA gels share a 23 mg/mL cross-linked hyaluronic-acid concentration; what varies across the line is the degree of cross-linking and the anesthetic):

1. Original Approval (October 19, 2017): The FDA approved P170002 for the three core strengths—RHA 2, RHA 3, and RHA 4—at 23 mg/mL cross-linked hyaluronic acid with 0.3% lidocaine hydrochloride. The approved indication was for the correction of moderate-to-severe dynamic facial wrinkles and folds, such as nasolabial folds, in adults aged 22 and older. This made them the first HA fillers specifically cleared for dynamic movement.
2. RHA Redensity Approval (December 22, 2021): Teoxane received U.S. FDA approval for RHA Redensity's first indication — the correction of moderate-to-severe superficial perioral rhytids (lipstick lines) — with a lower degree of cross-linking than RHA 2/3/4 for placement in the superficial dermis.
3. RHA Dynamic Volume Approval (January 13, 2026): This supplement expanded the portfolio into deep volume restoration, clearing RHA Dynamic Volume for cheek augmentation and the correction of age-related midface contour deficiencies in adults 22+. The approval was supported by a 52-week Phase 3 head-to-head study versus Juvéderm Voluma XC.
4. RHA Mepi (Mepivacaine) Line (2025): Teoxane and its U.S. distributor Revance Aesthetics received FDA approval and launched the "Mepi" versions of the RHA portfolio (e.g., RHA 2 Mepi, RHA 3 Mepi, RHA 4 Mepi, RHA Redensity Mepi), in which mepivacaine replaces lidocaine as the integrated anesthetic. Teoxane promotes this as the first major anesthetic innovation in HA fillers in nearly two decades, offering a clinical alternative for patients who experience excessive vasodilation or atypical swelling in response to lidocaine.

All RHA products are classified under the FDA product code LMH (Dermal Implant, Class III medical device). This regulatory footprint is summarized below:

---

What makes Resilient Hyaluronic Acid and Preserved Network Technology different from other HA fillers?

To contextualize the RHA Collection's clinical positioning, it is necessary to compare it to traditional HA fillers, such as Allergan's Juvéderm family or Galderma's Restylane family. Traditional fillers are characterized by high levels of chemical cross-linking designed to resist biodegradation. However, high cross-linking can make the gel stiff and rigid, reducing its ability to deform naturally under facial expressions.

Teoxane's solution is Resilient Hyaluronic Acid (RHA), manufactured using Preserved Network Technology (PNT).

Preserved Network Technology (PNT)

Traditional HA manufacturing processes utilize high temperatures and harsh chemical conditions to break down the natural, long-chain HA fibers, which are then re-linked using a chemical cross-linker (usually BDDE). This process destroys the native non-covalent interactions (hydrogen bonding and chain entanglement) that exist within natural hyaluronic acid.

PNT is a gentle, low-heat manufacturing process that preserves the natural, long-chain molecular structure of hyaluronic acid. By maintaining these long chains, PNT preserves the natural intermolecular forces:

1. Lower BDDE Requirement: Because the natural chain entanglement remains intact, RHA requires less chemical cross-linking to achieve stable gel properties. RHA fillers exhibit a modification rate (the percentage of HA units bound to BDDE) of approximately 1.9% to 4.0%, whereas traditional fillers often display modification rates of 5% to 10%.
2. Dynamic Network: The resulting gel behaves as a dynamic network. Under shear stress (e.g., smiling, chewing, talking), the long HA chains can slide past one another and stretch, absorbing the deformation. When the stress is removed, the natural chain entanglement pulls the gel back to its original shape.

Rheology Comparison: RHA vs. NASHA vs. Vycross

The physical differences between these platforms are defined by their rheological parameters:

• Elastic Modulus ($G'$, Pa): Represents the gel's firmness and resistance to deformation.
• Viscous Modulus ($G''$, Pa): Represents the gel's fluid-like behavior.
• Loss Tangent ($\tan \delta = G'' / G'$): Indicates whether the gel is more solid-like or fluid-like.
• Stretchability / Stretch Limit: The maximum strain a gel can undergo before its structure breaks down.

Traditional NASHA fillers (like Restylane Classic) have a high $G'$ but a low stretch limit; they provide strong support but can feel firm in highly mobile zones. Vycross fillers (like Juvéderm Volbella or Vollure) utilize a mix of low and high molecular weight HA to achieve high cohesivity but can sometimes feel dense. RHA fillers balance a moderate $G'$ with an exceptionally high stretch limit, enabling natural movement in dynamic wrinkles. We discuss this cross-linking science in depth in our guide to hyaluronic acid filler cross-linking.

   STRETCHABILITY COMPARISON UNDER SHEAR STRESS
   ┌────────────────────────────────────────────────────────┐
   │ [████████████████████████████████████████ ] Teoxane RHA│
   │ [████████████████████ ] Juvéderm Vycross               │
   │ [████████ ] Restylane NASHA                            │
   └────────────────────────────────────────────────────────┘

This flexibility allows Teoxane to market RHA as "the filler that moves with your face," positioning it as the preferred choice for areas subject to high muscular movement (nasolabial folds, perioral lines, oral commissures).

---

What does the MAUDE safety profile and zero-recall record show, and how should the single death report be read?

Evaluating the safety of Teoxane's portfolio requires analyzing the post-market surveillance data in the FDA's MAUDE database. A search of the database for confirmed Teoxane brands ("RHA" and "Teosyal") yields 712 total reports.

MAUDE Adverse Event Categories

The reporting profile is heavily dominated by physiological tissue responses:

• Injury Reports: 700 cases (98.3% of the dataset). These represent tissue-level reactions, including swelling, erythema, delayed-onset inflammatory nodules, infection, asymmetry, and vascular compromise.
• Malfunction Reports: 11 cases (1.5%). These represent device delivery issues, such as syringe plunger resistance or needle hub leaks.
• Death Reports: 1 case (0.1%).
• Recall Record: Teoxane/Revance has zero FDA recalls within the aesthetic device extract, demonstrating strong compliance and manufacturing consistency.

Brand-Specific Distribution of Reports

The MAUDE reports are distributed across Teoxane's global and U.S. brand names:

MAUDE REPORTS BY TEOXANE BRAND (Total: 712)
┌────────────────────────────────────────────────────────┐
│ [██████████ ] RHA 4 (127 reports)                      │
│ [█████████▊] Teosyal RHA 4 (123 reports)               │
│ [██████    ] Teosyal RHA 3 (69 reports)                │
│ [██████    ] Teosyal RHA 2 (68 reports)                │
│ [█████     ] RHA 3 (65 reports)                        │
│ [████      ] RHA 4 (no-space) (53 reports)             │
│ [███████████ ] Other / Mixed (207 reports)             │
└────────────────────────────────────────────────────────┘

RHA 4 and its international equivalent, Teosyal RHA 4, account for the highest proportion of reports (250 combined reports, representing 35.1% of the dataset). This is consistent with RHA 4's positioning as the firmest, most highly cross-linked variant in the collection, frequently injected deeper near mobile musculature or bone, where late-onset mechanical swelling or deep inflammatory nodules are more easily detected.

How to read the single death report

The MAUDE dataset contains one death report associated with a Teoxane product, filed under the global brand name TEOSYAL RHA3. Two points matter for a clinical or compliance reader:

1. Causation disclaimer. MAUDE is a passive surveillance system: manufacturers, healthcare professionals, and patients all file reports, and the FDA explicitly states that the presence of a report does not establish that the device caused or contributed to the event. A single report cannot be read as an incidence rate or a safety verdict.
2. No regulatory escalation. The FDA did not issue a recall, safety communication, or warning letter to Teoxane in connection with this report, and Teoxane has zero FDA recalls in the aesthetic device extract. The clinically meaningful signal in the RHA MAUDE set is the volume of injury-type reports (700 of 712) — swelling, erythema, delayed inflammatory nodules, and vascular-compromise presentations — not the single death entry. We have deliberately not paraphrased the narrative details of the individual report, because MAUDE case narratives are unverified and should be read in the primary record rather than summarized as established clinical fact.

Clinical Trial Evidence Depth

Teoxane's clinical profile is supported by 17 studies registered on ClinicalTrials.gov with Teoxane SA as lead sponsor. The pivotal evidence behind the U.S. approvals is published and FDA-reviewed:

The U.S. registration program (RHA 2, RHA 3, RHA 4)

The initial FDA approval of RHA 2, RHA 3, and RHA 4 rested on a prospective, multicenter, randomized, double-blind, within-subject (split-face) controlled trial of the resilient-HA gel (published as a 64-week nasolabial-fold study).

• Design: Roughly 140 subjects with moderate-to-severe nasolabial folds were randomized, with the active RHA gel injected in one nasolabial fold and an approved comparator HA filler (Restylane Lyft with lidocaine, a 20 mg/mL NASHA gel) in the contralateral fold; a separate untreated-control arm supported blinding.
• Efficacy measure: The 5-point Wrinkle Severity Rating Scale (WSRS), assessed by a blinded evaluator.
• Results: The RHA gel met non-inferiority versus the comparator at the primary timepoint, and a sustained responder advantage was tracked out to 64 weeks — supporting the "up to 15 months" durability claim for dynamic wrinkles and folds. The point of the program was to show that a lower-cross-linked, resilient gel did not trade away longevity for flexibility.

RHA Redensity (perioral rhytids)

RHA Redensity's superficial-perioral indication was supported by a prospective, randomized, evaluator-blinded, no-treatment-controlled study over 12 months, which is the basis for the "first and only FDA-approved HA filler for dynamic perioral rhytids" claim. Rather than quote per-timepoint responder rates that vary across the SSED and its post hoc analyses, the clinically useful takeaway is that a low-cross-linked gel could be placed safely in the superficial dermis (low Tyndall/nodule risk) while maintaining correction through one year.

---

Mepivacaine vs. Lidocaine: The Anesthetic Paradigm Shift

A key regulatory milestone for Teoxane is the introduction of mepivacaine hydrochloride as the integrated anesthetic in the RHA Mepi range. Historically, 0.3% lidocaine hydrochloride has been the standard local anesthetic integrated into dermal fillers to minimize pain during injection. However, mepivacaine presents distinct pharmacological characteristics that modify the injection experience and early tissue response.

1. Vasoactive Properties

A major pharmacological distinction between the two anesthetics is their effect on local vascular tone:

• Lidocaine: Acts as a vasodilator. When injected, it relaxes vascular smooth muscle, increasing local blood flow. In highly vascular zones (such as the lips or perioral region), this vasodilation can cause early swelling, erythema, and a higher risk of bruising.
• Mepivacaine: Displays mild vasoconstrictive properties at clinical concentrations. It constricts local microvessels, reducing blood flow to the immediate tissue. This vasoconstriction helps limit immediate post-injection swelling, minimizes bruising, and keeps the anesthetic localized, prolonging the pain-relief effect.

2. Onset and Duration of Action

Mepivacaine has a lower pKa (7.6) than lidocaine (7.9). Because it sits closer to physiological pH (7.4), a higher fraction of the drug remains in its un-ionized, lipid-soluble form at the time of injection. This enables faster penetration of nerve membranes, yielding a rapid anesthetic onset. Additionally, mepivacaine's mild vasoconstrictive action reduces its clearance by blood flow, providing a longer duration of local anesthesia.

3. Allergenic and Sensitivity Profiles

Mepivacaine belongs to the amide class of local anesthetics, making it compatible with patients who have amide-type sensitivities but display localized hypersensitivity to lidocaine or its preservatives. This provides clinicians with an alternative for patients who have previously experienced atypical swelling or flushing after lidocaine-containing fillers.

---

Clinical Decision Guide: Customizing RHA Selection by Motion Profile

Because the RHA Collection is built on dynamic integration, clinicians select products based on the target area's muscle activity (motion profile) and tissue depth. The matrix below outlines this selection logic:

1. High-Motion / Superficial Zones ( Lips, Perioral, Tear Trough)

• Clinical Challenge: Rigid fillers injected superficially can create visible ridges, nodules, or a blue hue under the skin (Tyndall effect) due to light scattering.
• RHA Selection: RHA Redensity or RHA 2.
• Rationale: RHA Redensity has the lowest modification rate (~1.9%) and the lowest elastic modulus ($G'$), allowing it to spread smoothly in the superficial dermis. It integrates between dermal collagen bundles without disrupting the skin surface during speech or smiling. RHA 2 provides soft volume for lip mucosal enhancement.

2. Moderate-Motion / Mid-Depth Zones ( Nasolabial Folds, Marionette Lines)

• Clinical Challenge: These areas require structural support to lift folds but are subject to constant shearing forces from the zygomaticus and orbicularis oris muscles.
• RHA Selection: RHA 3.
• Rationale: RHA 3 balances a moderate $G'$ (~150 Pa) with high stretchability. It provides the lift required to smooth deeper folds while adapting to lateral shearing forces, preventing the filler from splitting or shifting.

3. Low-Motion / Deep Structural Zones ( Cheeks, Jawline, Temple)

• Clinical Challenge: These zones require high projection and structural lift to restore volume over bone or deep subcutaneous fat.
• RHA Selection: RHA 4 or RHA Dynamic Volume.
• Rationale: RHA 4 and RHA Dynamic Volume carry the highest lift and $G'$ (firmness) in the collection. Placed supraperiosteally, they act as a stable cushion to lift the overlying tissue, while maintaining enough flexibility to avoid a rigid appearance when the patient smiles.

---

Hyaluronidase Reversibility Kinetics of Low-Crosslinked Gels

An important safety advantage of the RHA Collection is its high susceptibility to enzymatic degradation by hyaluronidase. If a vascular occlusion occurs or a patient requests filler dissolution, the speed of enzymatic breakdown is determined by the filler's cross-linking profile.

The Degradation Mechanism

Hyaluronidase works by cleaving the $\beta$-1,4-glucosidic bonds of the hyaluronic acid polymer chain. In highly cross-linked, dense HA gels (e.g., those using high-concentration BDDE or specialized high-density cross-linking), the chemical cross-links act as physical barriers, blocking the enzyme's access to the HA chains. This requires higher doses of hyaluronidase and repeated injections to dissolve the gel.

RHA Dissolution Kinetics

Because RHA is manufactured using Preserved Network Technology, it maintains a low rate of chemical modification (1.9% to 4.0% cross-linking) and relies on natural chain entanglement.

• Enzymatic Accessibility: The open, flexible network of RHA allows hyaluronidase to diffuse easily through the gel structure, gaining rapid access to the cleavage sites.
• Clinical Response: RHA fillers dissolve quickly and predictably when exposed to hyaluronidase. In cases of vascular occlusion, a standard dose of 150–300 units of hyaluronidase is typically sufficient to clear an RHA occlusion, compared to the higher, repeated doses often required for highly cross-linked, high-$G'$ fillers.

---

FAQ

Is the RHA Collection FDA-approved, and what is it cleared for?

Yes, the RHA Collection is FDA-approved under the single PMA family P170002. The individual products are cleared for specific indications: RHA 2, RHA 3, and RHA 4 are cleared for the correction of moderate-to-severe dynamic facial wrinkles and folds (such as nasolabial folds) in adults aged 22 and older; RHA Redensity is cleared for superficial perioral wrinkles (lipstick lines); and RHA Dynamic Volume is cleared for cheek augmentation to correct age-related midface volume deficit.

What is the difference between RHA 2, RHA 3, RHA 4, and RHA Redensity?

The differences are defined by their HA structure and physical properties (rheology):

• RHA Redensity: The lightest variant, possessing a very low cross-linking rate (~1.9%) and low firmness ($G'$). It is designed to stretch easily, making it optimal for superficial, delicate wrinkles around the mouth without causing lumpiness.
• RHA 2: A light-to-medium filler designed for moderate dynamic wrinkles and lip volume, injected into the mid-dermis.
• RHA 3: A medium-to-firm filler optimized for deep dynamic folds (such as nasolabial folds and marionette lines) and lip augmentation, injected into the deep dermis.
• RHA 4: The firmest filler in the dynamic collection, providing structural support in deep creases and the jawline, injected into the deep subdermal or subcutaneous plane.

---

Sources

1. FDA Premarket Approval (PMA) Database, P170002 (Teoxane RHA Collection): https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P170002
2. FDA Summary of Safety and Effectiveness Data (SSED), P170002 (RHA 2, RHA 3, RHA 4): https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170002B.pdf
3. Teoxane SA Innovation and Milestones (Geneva HQ, Preserved Network Technology, and Mepivacaine): https://www.teoxane.com/en/about-teoxane/milestones
4. RHA Collection - About Fillers and Resilient Hyaluronic Acid (Dynamic Wrinkles): https://www.rhacollection.com/about-fillers
5. FDA Center for Devices and Radiological Health, Premarket Approval Database: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm
6. FDA Adverse Event Reporting Systems (openFDA MAUDE Database for Medical Devices): https://open.fda.gov/apis/device/maude/
7. U.S. National Institutes of Health ClinicalTrials.gov registry (Lead Sponsor: Teoxane): https://clinicaltrials.gov/